Communiqués de presse Communiqués de presse14 septembre 202614 septembre 2026byDIAGNOS Navigation de l'article Ressource précédenteDIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026 Ressource suivanteDIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System Ressources connexe Communiqués de presse Investisseurs 03 2025 DIAGNOS DIAGNOS Announces Amendment to Convertible Debentures Télécharger le PDF Communiqués de presse Investisseurs 08 2022 DIAGNOS DIAGNOS Receives Regulatory Approval from the Costa Rica Health Agency for its Artificial Intelligence Enabled Pathology Detection Systems Télécharger le PDF Communiqués de presse Investisseurs 11 2024 DIAGNOS DIAGNOS Announces Cross listing of its Common Shares on the Frankfurt Stock Exchange Télécharger le PDF
Communiqués de presse Investisseurs 03 2025 DIAGNOS DIAGNOS Announces Amendment to Convertible Debentures Télécharger le PDF
Communiqués de presse Investisseurs 08 2022 DIAGNOS DIAGNOS Receives Regulatory Approval from the Costa Rica Health Agency for its Artificial Intelligence Enabled Pathology Detection Systems Télécharger le PDF
Communiqués de presse Investisseurs 11 2024 DIAGNOS DIAGNOS Announces Cross listing of its Common Shares on the Frankfurt Stock Exchange Télécharger le PDF
